ArticleThrombosis journal2025
Clinical features and risk factors for poor prognosis in malignant tumor patients with pulmonary embolism: a case control study.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary embolism (PE) is a significant cause of death in cancer patients. Although there are many reports on the clinical features and In-hospital prognosis for PE, but few studies on malignant tumors combined with pulmonary embolism. Early identification of high-risk populations, enhanced monitoring, and targeted therapeutic measures are crucial for improving patient prognosis. We conducted this study to identify reliable prognostic indicators through the analysis of real-world data.
methodsA total of 471 patients of malignant tumors complicated with PE were divided into two groups: (1) PE with poor prognosis group (n = 146). (2) PE without poor prognosis group (n = 325). Clinical characteristics, laboratory parameters and adverse prognostic events were recorded and analyzed.
resultsHigh diastolic blood pressure (Odds Ratio [OR] = 1.819, 95% confidence interval [CI]: 1.144–2.893, p = 0.011), myoglobin (MYO) (OR = 3.283, 95% CI: 2.016–5.347, p < 0.001), procalcitonin (PCT) (OR = 2.530, 95% CI: 1.581–4.049, p < 0.001), pleural effusion (OR = 1.618, 95% CI: 1.013–2.584, p = 0.044) and invasive surgery (OR = 2.339, 95% CI: 1.471–3.719, p < 0.001) were found to be independent risk factors for poor prognosis in malignant tumor patients with PE. The ROC curve analysis showed that the area under the curve (AUC) for MYO and PCT were 0.683 and 0.657, respectively. The combined predictive value of MYO and PCT was 0.704.
conclusionHigh diastolic blood pressure, MYO, PCT, pleural effusion, invasive surgery were proved to be independent risk factors for poor prognosis in malignant tumor patients with PE. In biomarkers, the indicator of MYO combined with PCT shows the highest predictive value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.